All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Incyte, Genesis Therapeutics enter AI-focused research collaboration
Genesis will receive $30m in upfront payment and is eligible to receive up to $295m in development, regulatory and commercial milestone payments per target, and receive tiered royalties on net sales of products
Nucala (mepolizumab) application for COPD accepted for review in China
Submission based on data from MATINEE trial, which showed a significant and clinically meaningful reduction in rate of moderate/severe exacerbations with Nucala compared to placebo
Merck, Epitopea partner to identify Cryptigen tumour-specific antigens
Cryptigen TSAs are shared, non-mutated, aberrantly expressed antigens that are derived from junk DNA, thought to be non-coding regions of the genome, discovered using Epitopea’s CryptoMap platform
AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease investigational gene therapy
Study demonstrated favorable safety profile and continued positive trends in assessed clinical outcome measures of the investigational gene therapy AB-1005
Biogen partners with Stoke to develop treatment for rare brain disorder
Stoke Therapeutics will receive $165m in upfront payment and is eligible to receive up to $385m in development and commercial milestone payments, along with tiered on potential net sales in the Biogen territory
Avenacy Announces Launch of Zoledronic Acid Injection, USP in the U.S. Market
Zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy
Cellistic rolls out Allo Chassis platform for cell therapy development
Cellistic developed the Allo Chassis platform using its expertise in iPSCs, including T-cell-based treatments, under current Good Manufacturing Practice (cGMP) standards, to enhance global access to cell therapy
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI (mirdametinib), Manufactured By SpringWorks Therapeutics
Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers
Sanofi secures FDA approval for Novolog biosimilar Merilog
Merilog is a rapid-acting human insulin analogue that works to reduce mealtime blood sugar spikes to improve control of blood sugar in people with diabetes
Zoetis Receives Conditional License from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus
Zoetis is committed to supporting poultry producers with scientific solutions for Highly Pathogenic Avian Influenza (HPAI)